Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

The PDL1-inducible GTPase Arl4d controls T effector function by limiting IL-2 production.

Tolksdorf F, Mikulec J, Geers B, Endig J, Sprezyna P, Heukamp LC, Knolle PA, Kolanus W, Diehl L.

Sci Rep. 2018 Oct 31;8(1):16123. doi: 10.1038/s41598-018-34522-4.

2.

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC).

Frank R, Scheffler M, Merkelbach-Bruse S, Ihle MA, Kron A, Rauer M, Ueckeroth F, König K, Michels S, Fischer R, Eisert A, Fassunke J, Heydt C, Serke M, Ko YD, Gerigk U, Geist T, Kaminsky B, Heukamp LC, Clement-Ziza M, Büttner R, Wolf J.

Clin Cancer Res. 2018 Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416. Epub 2018 Apr 3.

3.

LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model.

Meder L, König K, Dietlein F, Macheleidt I, Florin A, Ercanoglu MS, Rommerscheidt-Fuss U, Koker M, Schön G, Odenthal M, Klein F, Büttner R, Schulte JH, Heukamp LC, Ullrich RT.

Oncogene. 2018 May;37(20):2746-2756. doi: 10.1038/s41388-018-0158-7. Epub 2018 Mar 5.

PMID:
29503447
4.

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non-Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy.

Lakis S, Heukamp LC, Griesinger F.

J Thorac Oncol. 2017 Nov;12(11):e186-e188. doi: 10.1016/j.jtho.2017.07.018. No abstract available.

5.

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.

Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Örfi L, Kéri G, Ansén S, Heukamp LC, Büttner R, Rauh D, Klebl BM, Thomas RK, Sos ML.

Cell Rep. 2017 Sep 19;20(12):2833-2845. doi: 10.1016/j.celrep.2017.08.082.

6.

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC, Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU, Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J.

Histopathology. 2018 Feb;72(3):449-459. doi: 10.1111/his.13375. Epub 2017 Nov 21.

PMID:
28851100
7.

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens.

Müller JN, Falk M, Talwar J, Neemann N, Mariotti E, Bertrand M, Zacherle T, Lakis S, Menon R, Gloeckner C, Tiemann M, Heukamp LC, Thomas RK, Griesinger F, Heuckmann JM.

J Thorac Oncol. 2017 Oct;12(10):1503-1511. doi: 10.1016/j.jtho.2017.07.014. Epub 2017 Jul 24.

8.

Correction: Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine.

Ladang A, Rapino F, Heukamp LC, Tharun L, Shostak K, Hermand D, Delaunay S, Klevernic I, Jiang Z, Jacques N, Jamart D, Migeot V, Florin A, Göktuna S, Malgrange B, Sansom OJ, Nguyen L, Büttner R, Close P, Chariot A.

J Exp Med. 2017 Apr 3;214(4):1199. doi: 10.1084/jem.2014228803082017c. Epub 2017 Mar 10. No abstract available.

9.

[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Büttner R.

Pathologe. 2016 Nov;37(6):557-567. Review. German.

PMID:
27510417
10.

Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.

Latteyer S, Tiedje V, König K, Ting S, Heukamp LC, Meder L, Schmid KW, Führer D, Moeller LC.

Endocrine. 2016 Dec;54(3):733-741. doi: 10.1007/s12020-016-1080-9. Epub 2016 Oct 1.

PMID:
27696251
11.

Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.

Rosoux A, Pauwels P, Duplaquet F, D'Haene N, Weynand B, Delos M, Menon R, Heukamp LC, Thunnissen E, Ocak S.

Lung Cancer. 2016 Aug;98:118-121. doi: 10.1016/j.lungcan.2016.06.001. Epub 2016 Jun 3.

PMID:
27393517
12.

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Buettner R.

Mod Pathol. 2016 Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117. Epub 2016 Jul 8.

13.

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.

Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML.

Clin Cancer Res. 2016 Oct 1;22(19):4837-4847. Epub 2016 Jun 1.

14.

Retraction Notice to: Cytohesins Are Cytoplasmic ErbB Receptor Activators.

Bill A, Schmitz A, Albertoni B, Song JN, Heukamp LC, Walrafen D, Thorwirth F, Verveer PJ, Zimmer S, Meffert L, Schreiber A, Chatterjee S, Thomas RK, Ullrich RT, Lang T, Famulok M.

Cell. 2016 May 19;165(5):1293. doi: 10.1016/j.cell.2016.05.013. No abstract available.

15.

The Prosurvival IKK-Related Kinase IKKε Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine.

Göktuna SI, Shostak K, Chau TL, Heukamp LC, Hennuy B, Duong HQ, Ladang A, Close P, Klevernic I, Olivier F, Florin A, Ehx G, Baron F, Vandereyken M, Rahmouni S, Vereecke L, van Loo G, Büttner R, Greten FR, Chariot A.

Cancer Res. 2016 May 1;76(9):2587-99. doi: 10.1158/0008-5472.CAN-15-1473. Epub 2016 Mar 15.

16.

Successful AZD9291 Therapy Based on Circulating T790M.

Gautschi O, Aebi S, Heukamp LC.

J Thorac Oncol. 2015 Dec;10(12):e122-3. doi: 10.1097/JTO.0000000000000676. No abstract available.

17.

Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.

Vollbrecht C, Werner R, Walter RF, Christoph DC, Heukamp LC, Peifer M, Hirsch B, Burbat L, Mairinger T, Schmid KW, Wohlschlaeger J, Mairinger FD.

Br J Cancer. 2015 Dec 22;113(12):1704-11. doi: 10.1038/bjc.2015.397. Epub 2015 Dec 8.

18.

Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.

Gautschi O, Stadelmann C, Aebersold-Keller F, König K, Büttner R, Heukamp LC, Betticher D, Baumann C, Buser K, Calderoni A, Casty A, DʼAddario G, Irlé C, Mamot C, Morant R, Trojan A, Pellicioli E, Jehle-Schwertfeger S, Aebi S, Diebold J.

Oncol Res Treat. 2015;38(11):560-9. doi: 10.1159/000441367. Epub 2015 Oct 21.

PMID:
26599269
19.

Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.

Meder L, König K, Fassunke J, Ozretić L, Wolf J, Merkelbach-Bruse S, Heukamp LC, Buettner R.

Exp Mol Pathol. 2015 Dec;99(3):682-6. doi: 10.1016/j.yexmp.2015.11.002. Epub 2015 Nov 10.

PMID:
26546837
20.

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.

Schöttle J, Chatterjee S, Volz C, Siobal M, Florin A, Rokitta D, Hinze Y, Dietlein F, Plenker D, König K, Albus K, Heuckmann JM, Rauh D, Franz T, Neumaier B, Fuhr U, Heukamp LC, Ullrich RT.

Oncotarget. 2015 Nov 17;6(36):38458-68. doi: 10.18632/oncotarget.6276.

21.

Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine.

Ladang A, Rapino F, Heukamp LC, Tharun L, Shostak K, Hermand D, Delaunay S, Klevernic I, Jiang Z, Jacques N, Jamart D, Migeot V, Florin A, Göktuna S, Malgrange B, Sansom OJ, Nguyen L, Büttner R, Close P, Chariot A.

J Exp Med. 2015 Nov 16;212(12):2057-75. doi: 10.1084/jem.20142288. Epub 2015 Nov 2. Erratum in: J Exp Med. 2017 Apr 3;214(4):1199.

22.

Endogenous Il10 alleviates the systemic antiviral cellular immune response and T cell-mediated immunopathology in select organs of acutely LCMV-infected mice.

Jakobshagen K, Ward B, Baschuk N, Huss S, Brunn A, Malecki M, Fiolka M, Rappl G, Corogeanu D, Karow U, Schiller P, Abken H, Heukamp LC, Deckert M, Krönke M, Utermöhlen O.

Am J Pathol. 2015 Nov;185(11):3025-38. doi: 10.1016/j.ajpath.2015.07.019.

PMID:
26506472
23.

[Cytological material for molecular pathology].

Heukamp LC, Bubendorf L.

Pathologe. 2015 Nov;36(6):566-71. Review. German.

PMID:
26483251
24.

NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, Buhl T, Hartmann W, Wolf J, Merkelbach-Bruse S, Eilers M, Perner S, Heukamp LC, Buettner R.

Int J Cancer. 2016 Feb 15;138(4):927-38. doi: 10.1002/ijc.29835. Epub 2015 Sep 25.

25.

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

König K, Peifer M, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Stamm K, Ueckeroth F, Vollbrecht C, Bos M, Gardizi M, Scheffler M, Nogova L, Leenders F, Albus K, Meder L, Becker K, Florin A, Rommerscheidt-Fuss U, Altmüller J, Kloth M, Nürnberg P, Henkel T, Bikár SE, Sos ML, Geese WJ, Strauss L, Ko YD, Gerigk U, Odenthal M, Zander T, Wolf J, Merkelbach-Bruse S, Buettner R, Heukamp LC.

J Thorac Oncol. 2015 Jul;10(7):1049-57. doi: 10.1097/JTO.0000000000000570.

26.

Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing.

Vollbrecht C, Mairinger FD, Koitzsch U, Peifer M, Koenig K, Heukamp LC, Crispatzu G, Wilden L, Kreuzer KA, Hallek M, Odenthal M, Herling CD, Buettner R.

PLoS One. 2015 Jun 8;10(6):e0129544. doi: 10.1371/journal.pone.0129544. eCollection 2015.

27.

Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.

Grünewald I, Vollbrecht C, Meinrath J, Meyer MF, Heukamp LC, Drebber U, Quaas A, Beutner D, Hüttenbrink KB, Wardelmann E, Hartmann W, Büttner R, Odenthal M, Stenner M.

Oncotarget. 2015 Jul 20;6(20):18224-37.

28.

Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.

Kloth M, Ruesseler V, Engel C, Koenig K, Peifer M, Mariotti E, Kuenstlinger H, Florin A, Rommerscheidt-Fuss U, Koitzsch U, Wodtke C, Ueckeroth F, Holzapfel S, Aretz S, Propping P, Loeffler M, Merkelbach-Bruse S, Odenthal M, Friedrichs N, Heukamp LC, Zander T, Buettner R.

Gut. 2016 Aug;65(8):1296-305. doi: 10.1136/gutjnl-2014-309026. Epub 2015 Apr 28.

PMID:
26001389
29.

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

Scheffler M, Merkelbach-Bruse S, Bos M, Fassunke J, Gardizi M, Michels S, Groneck L, Schultheis AM, Malchers F, Leenders F, Kobe C, König K, Heukamp LC, Sos ML, Thomas RK, Büttner R, Wolf J.

J Thorac Oncol. 2015 Jun;10(6):e40-3. doi: 10.1097/JTO.0000000000000503. No abstract available.

30.

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.

Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, Heydt C, Künstlinger H, Ihle M, Ueckeroth F, Albus K, Serke M, Gerigk U, Schulte W, Töpelt K, Nogova L, Zander T, Engel-Riedel W, Stoelben E, Ko YD, Randerath W, Kaminsky B, Panse J, Becker C, Hellmich M, Merkelbach-Bruse S, Heukamp LC, Büttner R, Wolf J.

Oncotarget. 2015 Jan 20;6(2):1315-26.

31.

Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma.

Theurich S, Schlaak M, Steguweit H, Heukamp LC, Wennhold K, Kurschat P, Rabenhorst A, Hartmann K, Schlösser H, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Stadler R, von Bergwelt-Baildon M.

J Clin Oncol. 2016 Apr 20;34(12):e110-6. doi: 10.1200/JCO.2013.50.9471. Epub 2014 Oct 27. No abstract available.

PMID:
25348001
32.

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.

Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprüssel A, Lindner S, De Preter K, Florin A, Heukamp LC, Klein-Hitpass L, Astrahantseff K, Kumps C, Speleman F, Eggert A, Westermann F, Schramm A, Schulte JH.

Oncogene. 2015 Jun;34(26):3357-68. doi: 10.1038/onc.2014.269. Epub 2014 Sep 1.

33.

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W.

Nat Med. 2014 Sep;20(9):1027-34. doi: 10.1038/nm.3667. Epub 2014 Aug 31.

34.

Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnostics.

Heydt C, Fassunke J, Künstlinger H, Ihle MA, König K, Heukamp LC, Schildhaus HU, Odenthal M, Büttner R, Merkelbach-Bruse S.

PLoS One. 2014 Aug 8;9(8):e104566. doi: 10.1371/journal.pone.0104566. eCollection 2014.

35.

Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma.

Schütte U, Bisht S, Heukamp LC, Kebschull M, Florin A, Haarmann J, Hoffmann P, Bendas G, Buettner R, Brossart P, Feldmann G.

Transl Oncol. 2014 Apr;7(2):309-21. doi: 10.1016/j.tranon.2014.02.005. Epub 2014 Mar 4.

36.

The LIM-only protein FHL2 reduces vascular lesion formation involving inhibition of proliferation and migration of smooth muscle cells.

Kurakula K, Vos M, Otermin Rubio I, Marinković G, Buettner R, Heukamp LC, Stap J, de Waard V, van Tiel CM, de Vries CJ.

PLoS One. 2014 Apr 15;9(4):e94931. doi: 10.1371/journal.pone.0094931. eCollection 2014.

37.

Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.

Chatterjee S, Wieczorek C, Schöttle J, Siobal M, Hinze Y, Franz T, Florin A, Adamczak J, Heukamp LC, Neumaier B, Ullrich RT.

Cancer Res. 2014 May 15;74(10):2816-24. doi: 10.1158/0008-5472.CAN-13-2986. Epub 2014 Mar 27.

38.

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.

Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z, Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I, Perner S, Lovly C, Cappuzzo F, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK.

Nat Commun. 2014 Mar 27;5:3518. doi: 10.1038/ncomms4518.

39.

Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.

Fuchs A, König K, Heukamp LC, Fassunke J, Kirfel J, Huss S, Becker AJ, Büttner R, Majores M.

Diagn Pathol. 2014 Mar 4;9:48. doi: 10.1186/1746-1596-9-48.

40.

Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer.

Ellinger J, Bachmann A, Göke F, Behbahani TE, Baumann C, Heukamp LC, Rogenhofer S, Müller SC.

Urol Int. 2014;93(1):113-8. doi: 10.1159/000355467. Epub 2014 Feb 18.

PMID:
24556868
41.

A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC.

Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC.

Cancer Discov. 2014 May;4(5):592-605. doi: 10.1158/2159-8290.CD-13-0907. Epub 2014 Feb 20.

42.

CD74-NRG1 fusions in lung adenocarcinoma.

Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, Ortiz-Cuaran S, Peifer M, Bos M, Daßler J, Malchers F, Schöttle J, Vogel W, Dahmen I, Koker M, Ullrich RT, Wright GM, Russell PA, Wainer Z, Solomon B, Brambilla E, Nagy-Mignotte H, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Altmüller J, Becker C, Nürnberg P, Heuckmann JM, Stoelben E, Petersen I, Clement JH, Sänger J, Muscarella LA, la Torre A, Fazio VM, Lahortiga I, Perera T, Ogata S, Parade M, Brehmer D, Vingron M, Heukamp LC, Buettner R, Zander T, Wolf J, Perner S, Ansén S, Haas SA, Yatabe Y, Thomas RK.

Cancer Discov. 2014 Apr;4(4):415-22. doi: 10.1158/2159-8290.CD-13-0633. Epub 2014 Jan 27.

43.

Analysis of TET expression/activity and 5mC oxidation during normal and malignant germ cell development.

Nettersheim D, Heukamp LC, Fronhoffs F, Grewe MJ, Haas N, Waha A, Honecker F, Waha A, Kristiansen G, Schorle H.

PLoS One. 2013 Dec 26;8(12):e82881. doi: 10.1371/journal.pone.0082881. eCollection 2013.

44.

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.

Malchers F, Dietlein F, Schöttle J, Lu X, Nogova L, Albus K, Fernandez-Cuesta L, Heuckmann JM, Gautschi O, Diebold J, Plenker D, Gardizi M, Scheffler M, Bos M, Seidel D, Leenders F, Richters A, Peifer M, Florin A, Mainkar PS, Karre N, Chandrasekhar S, George J, Silling S, Rauh D, Zander T, Ullrich RT, Reinhardt HC, Ringeisen F, Büttner R, Heukamp LC, Wolf J, Thomas RK.

Cancer Discov. 2014 Feb;4(2):246-57. doi: 10.1158/2159-8290.CD-13-0323. Epub 2013 Dec 3.

45.

The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.

Pajtler KW, Weingarten C, Thor T, Künkele A, Heukamp LC, Büttner R, Suzuki T, Miyata N, Grotzer M, Rieb A, Sprüssel A, Eggert A, Schramm A, Schulte JH.

Acta Neuropathol Commun. 2013 May 29;1:19. doi: 10.1186/2051-5960-1-19.

46.

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.

Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Keßler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, Borchmann P, Yazaki P, Koslowsky TC, Engert A, Heukamp LC, Hallek M, von Strandmann EP.

Int J Cancer. 2014 Jun 15;134(12):2829-40. doi: 10.1002/ijc.28609. Epub 2013 Nov 29.

47.

Targeted Therapy for Neuroblastoma: ALK Inhibitors.

Schulte JH, Schulte S, Heukamp LC, Astrahantseff K, Stephan H, Fischer M, Schramm A, Eggert A.

Klin Padiatr. 2013 Nov;225(6):303-8. doi: 10.1055/s-0033-1357132. Epub 2013 Oct 28. Review.

PMID:
24166094
48.

Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.

Höchst B, Schildberg FA, Sauerborn P, Gäbel YA, Gevensleben H, Goltz D, Heukamp LC, Türler A, Ballmaier M, Gieseke F, Müller I, Kalff J, Kurts C, Knolle PA, Diehl L.

J Hepatol. 2013 Sep;59(3):528-35. doi: 10.1016/j.jhep.2013.04.033. Epub 2013 May 9.

PMID:
23665041
49.

Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues.

Becker K, Vollbrecht C, Koitzsch U, Koenig K, Fassunke J, Huss S, Nuernberg P, Heukamp LC, Buettner R, Odenthal M, Altmueller J, Merkelbach-Bruse S.

J Clin Pathol. 2013 Sep;66(9):803-6. doi: 10.1136/jclinpath-2013-201549. Epub 2013 Apr 25.

PMID:
23618693
50.

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.

Bos M, Gardizi M, Schildhaus HU, Heukamp LC, Geist T, Kaminsky B, Zander T, Nogova L, Scheffler M, Dietlein M, Kobe C, Holstein A, Maintz D, Büttner R, Wolf J.

Lung Cancer. 2013 Jul;81(1):142-3. doi: 10.1016/j.lungcan.2013.02.018. Epub 2013 Apr 1.

PMID:
23558310

Supplemental Content

Loading ...
Support Center